Spero Therapeutics (NASDAQ:SPRO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

SPRO has been the subject of several other reports. Janney Montgomery Scott initiated coverage on Spero Therapeutics in a research report on Monday. They set a “buy” rating for the company. TheStreet cut Spero Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 29th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Spero Therapeutics in a research report on Wednesday, September 4th. Finally, ValuEngine cut Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. Spero Therapeutics has an average rating of “Hold” and an average target price of $21.20.

Shares of Spero Therapeutics stock traded down $0.20 during trading hours on Thursday, hitting $12.35. The company’s stock had a trading volume of 331 shares, compared to its average volume of 64,916. Spero Therapeutics has a 12 month low of $5.52 and a 12 month high of $14.48. The stock has a 50 day moving average of $9.97 and a 200 day moving average of $11.46. The company has a market capitalization of $207.08 million, a PE ratio of -4.83 and a beta of 2.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 13.66 and a quick ratio of 13.66.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Spero Therapeutics had a negative return on equity of 33.84% and a negative net margin of 321.37%. The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $6.95 million. Equities analysts expect that Spero Therapeutics will post -2.9 EPS for the current year.

Several hedge funds have recently bought and sold shares of SPRO. Bank of America Corp DE boosted its position in shares of Spero Therapeutics by 2,036.1% during the fourth quarter. Bank of America Corp DE now owns 83,009 shares of the company’s stock worth $510,000 after buying an additional 79,123 shares during the period. Marshall Wace LLP acquired a new position in Spero Therapeutics during the first quarter valued at approximately $39,000. Wells Fargo & Company MN boosted its position in Spero Therapeutics by 187.9% during the second quarter. Wells Fargo & Company MN now owns 13,660 shares of the company’s stock valued at $157,000 after purchasing an additional 8,915 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Spero Therapeutics by 9.2% during the second quarter. JPMorgan Chase & Co. now owns 164,389 shares of the company’s stock valued at $1,826,000 after purchasing an additional 13,814 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Spero Therapeutics during the second quarter valued at approximately $25,000. 50.97% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections.

See Also: Recession

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.